We finally aimed to determine whether these 3 groups of ER + /HER2- tumors, stratified according to HRD status, would have different prognosis, and how this new biological segmentation could account for the risk of relapse and death, compared to previously described, classical prognostic factors, and biological factors related to the tumor microenvironment. The gene discussed is ERBB2; the disease is neoplasm.